NY-IFF
25.6.2020 14:02:08 CEST | Business Wire | Press release
Regulatory News:
IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, and nutrition, today published its 2019 Sustainability Report, “Do More Good.” The title references a pillar of the Company’s purpose, To redefine how we live in and care for the resources of our world , which was launched last year as part of its most significant rebrand in 40 years. The report highlights IFF’s sustainability accomplishments throughout the business and covers the Company’s achievements in leveraging sustainable practices within its global footprint.
Andreas Fibig, IFF Chairman and CEO, said: “The leadership position that we have taken in sustainability is a reflection of the passion to do more good that’s been embraced by our people everywhere at IFF. We credit our customers, partners and suppliers for the incredible and productive alliances we have forged together in the service of sustainability. This is not a journey we can – or want - to take alone. It requires the energy and commitment of like-minded allies willing to challenge the status quo – and each other – to do what is ultimately best for people and planet.”
The 2019 report highlights include:
- IFF’s new purpose and Vision 2021 strategy, reflecting the importance of sustainability as a way of doing business at IFF
- External recognitions for IFF’s sustainability leadership, such as Barron’s, FTSE4Good, RobecoSAM Industry Mover award, Euronext Vigeo, and CDP A list
- Continued commitment to climate action, as demonstrated by the opening of the Union Beach, New Jersey solar array, the signing of the U.N. Business Ambition for 1.5°C: Our Only Future pledge, and strong progress against its environmental goals for greenhouse gas emission reductions (including a decrease in absolute emissions of 5.7% from prior year), and zero waste to landfill and water stewardship
- Strengthening of IFF’s responsible sourcing program and natural ingredient supply chains through new certifications, as well as by accelerating industry-leading blockchain technology as a tool for ensuring ingredient traceability
- Achieving an industry breakthrough in circular design and transparency with Henry Rose, a line of fine fragrances founded by actress Michelle Pfeiffer and created to the strictest environmental standards as defined by the Environmental Working Group and the Cradle to Cradle Products Innovation Institute
- External recognitions and certifications for IFF’s diversity & inclusion leadership, such as DiversityInc., Human Rights Campaign, EDGE, and the signing of the U.N. Global LGBTI Standards of Conduct for Business and the U.N. Women’s Empowerment Principles
- Accelerated the inclusion of legacy Frutarom data, where available, in response to stakeholder interest and to prepare for the anticipated merger with DuPont’s Nutrition & Biosciences business. This process included a significant data collection and training effort for more than 60 facilities in 27 countries.
Dr. Greg Yep, IFF’s Chief Scientific & Sustainability Officer, said, “IFF’s sustainability accomplishments are considerable and meaningful and I must thank our global network of green teams who are empowered to drive change for IFF and our communities. As pleased as we are with our results, from external recognitions to meeting and exceeding our goals, I know I speak for all of IFF when I confirm our commitment to continually improve and drive better outcomes, and always seeks ways to live up to our purpose and do more good.”
To read IFF’s 2019 Sustainability Report, visit iff.com/sustain and use #SustainxIFF to follow the conversation on its social channels.
# # #
Welcome to IFF
At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005417/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
